# An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Study · id `cardio:ct-nct01151410` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01151410](<https://clinicaltrials.gov/study/NCT01151410>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01151410

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.

## Technical summary

Registry record NCT01151410. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2016-03-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 208 participants (enrolled count; ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Results first posted: 2016-03-07 (ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Countries: United States; Guatemala; Hungary; Poland; Puerto Rico; Slovakia; Türkiye (ClinicalTrials.gov record NCT01151410, source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01151410-2016-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
- Condition: Hypertension
- Intervention (Drug): Aliskiren
- Intervention (Drug): Enalapril
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 3ed130a527fa7bf436109c17c649cc027e02730ed844b15c1299e06d36f006b0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
